Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00021723
Status:
TERMINATED
Last Update Posted:
2009-09-24
First Post:
2001-08-02
Brief Title:
Randomized Safety Tolerability and Pilot Efficacy of AN-1792 in Alzheimers Disease
Sponsor:
JANSSEN Alzheimer Immunotherapy Research Development LLC
Organization:
JANSSEN Alzheimer Immunotherapy Research Development LLC
Study Overview
Official Title:
None
Status:
TERMINATED
Status Verified Date:
2001-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A multi-center double-blind placebo-controlled out-patient safety tolerability and pilot efficacy study of intramuscular AN-1792 in patients with mild to moderate Alzheimers disease
Detailed Description:
The study will enroll approximately 375 patients with mild to moderate Alzheimers disease at investigational sites in the United States and Europe Patients will receive either AN-1792 or placebo and they will be evaluated using standard clinical assessments of cognition and memory as well as experimental surrogate markers of Alzheimers disease pathology The goal of the study is to evaluate the clinical impact of eliciting an immune response formation of antibodies to the A-beta peptide in patients with Alzheimers disease
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None